Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 74-77, 2013.
Article
em En
| WPRIM
| ID: wpr-213728
Biblioteca responsável:
WPRO
ABSTRACT
Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. Pemetrexed has a modest toxicity profile and has not traditionally been regarded as a cause of interstitial pneumonitis. Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Pneumonia
/
Adenocarcinoma
/
Cisplatino
/
Doenças Pulmonares Intersticiais
/
Carcinoma Pulmonar de Células não Pequenas
/
Progressão da Doença
/
Quimioterapia de Indução
/
Pemetrexede
/
Glutamatos
/
Guanina
Limite:
Humans
Idioma:
En
Revista:
Cancer Research and Treatment
Ano de publicação:
2013
Tipo de documento:
Article